Clinical FDG-PET use grows as research moves forward

March 4, 2008 Diagnostic Imaging. Clinical FDG-PET use grows as research moves forward Discoveries chart course toward earlier diagnoses and more effective treatments for cancer, cardiovascular disease, and dementia James Brice -------------------------------------------------------------------------------- Molecular imaging has been redefined. By expanding its definition to apply to most diagnostic and therapeutic procedures formerly associated with nuclear medicine, diagnostic imaging’s leaders hope to make molecular imaging relevant and accessible to mainstream radiology. MI’s journey from bench to bedside is not going to be easy. Researchers need more time to guide promising applications from preclinical animal testing into practice. Yet progress can be seen on several fronts. In particular, the National Oncology PET Registry, implemented in mid-2006, has greatly expanded Medicare coverage for FDG-PET and raised the visibility of PET imaging for cancer staging and the monitoring of cancer therapies.

See full article and related articles at DiagnosticImaging.com
This article was republished with permission from CMPMedica, LLC